Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis

Trial Profile

Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Certolizumab pegol (Primary)
  • Indications Interstitial cystitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Mar 2017 Planned End Date changed from 1 May 2018 to 1 Jul 2017.
    • 01 Mar 2017 Planned primary completion date changed from 1 Dec 2017 to 1 May 2017.
    • 01 Mar 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top